Blood tests could reduce lung cancer deaths, study finds
Biomarkers found in the blood can reveal changes in the body that may signal lung cancer before symptoms appear.
Blood test proven to 'detect cancer earlier and reduce deaths'
The blood test for those at high risk of lung cancer could lead to earlier detection and a "major reduction" in deaths, a ...
vator1d
Oxford Cancer Analytics raises $11M to detect lung cancer via a blood test
This latest investment, which brings OXcan’s total funding to date to $16.7 million, will be used to develop and globally ...
TMCnet1d
Oxford Cancer Analytics Raises USD$11M in Series A Funding to Transform Early Lung Cancer Detection and Enable Curative Treatments
Oxford Cancer Analytics (OXcan), the medtech company developing blood tests for early cancer detection using advanced proteomics and AI, today announced it has raised US$11 million in Series A funding ...
Biomarker test for lung cancer cuts deaths by 40 per cent
Groundbreaking research from the University of St Andrews School of Medicine has found that biomarker testing in individuals ...
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
The Nodify CDT test measures levels of seven autoantibodies associated with lung cancer that can be detected in blood samples of patients with indeterminate lung nodules. Prior studies have ...
Zacks.com on MSN2d
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test
Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.
BetaKit1d
Doctor-led Oxford Cancer Analytics closes $16-million CAD Series A to improve early lung cancer detection
Oxford, UK and Toronto-based OXcan has secured over $11 million USD in Series A funding to develop and deploy its ...
Biodesix announces publication of new Nodify CDT clinical validation study
Biodesix (BDSX) announced a new post-market clinical validation study was published in CHEST Pulmonary Journal that reaffirms the previously ...